JP2023516957A - ダプトマイシン製剤 - Google Patents

ダプトマイシン製剤 Download PDF

Info

Publication number
JP2023516957A
JP2023516957A JP2022551653A JP2022551653A JP2023516957A JP 2023516957 A JP2023516957 A JP 2023516957A JP 2022551653 A JP2022551653 A JP 2022551653A JP 2022551653 A JP2022551653 A JP 2022551653A JP 2023516957 A JP2023516957 A JP 2023516957A
Authority
JP
Japan
Prior art keywords
daptomycin
formulation
solid
reconstitution time
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516957A5 (enExample
Inventor
フミッチ、バルバラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xellia Pharmaceuticals ApS
Original Assignee
Xellia Pharmaceuticals ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals ApS filed Critical Xellia Pharmaceuticals ApS
Publication of JP2023516957A publication Critical patent/JP2023516957A/ja
Publication of JP2023516957A5 publication Critical patent/JP2023516957A5/ja
Priority to JP2025120933A priority Critical patent/JP2025142200A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022551653A 2020-02-28 2021-02-26 ダプトマイシン製剤 Pending JP2023516957A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120933A JP2025142200A (ja) 2020-02-28 2025-07-18 ダプトマイシン製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982945P 2020-02-28 2020-02-28
US62/982,945 2020-02-28
PCT/EP2021/054841 WO2021170807A1 (en) 2020-02-28 2021-02-26 Daptomycin formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120933A Division JP2025142200A (ja) 2020-02-28 2025-07-18 ダプトマイシン製剤

Publications (2)

Publication Number Publication Date
JP2023516957A true JP2023516957A (ja) 2023-04-21
JP2023516957A5 JP2023516957A5 (enExample) 2023-12-07

Family

ID=74797935

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022551653A Pending JP2023516957A (ja) 2020-02-28 2021-02-26 ダプトマイシン製剤
JP2025120933A Pending JP2025142200A (ja) 2020-02-28 2025-07-18 ダプトマイシン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120933A Pending JP2025142200A (ja) 2020-02-28 2025-07-18 ダプトマイシン製剤

Country Status (10)

Country Link
US (1) US20230068866A1 (enExample)
EP (1) EP4110303A1 (enExample)
JP (2) JP2023516957A (enExample)
CN (2) CN118873500A (enExample)
AU (1) AU2021227095B2 (enExample)
BR (1) BR112022015571A2 (enExample)
CA (1) CA3168727A1 (enExample)
MX (1) MX2022010378A (enExample)
WO (1) WO2021170807A1 (enExample)
ZA (1) ZA202208343B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2770366C2 (ru) 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003055256A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
WO2019043008A1 (en) * 2017-08-31 2019-03-07 Xellia Pharmaceuticals Aps DAPTOMYCIN FORMULATIONS
WO2019096776A1 (en) * 2017-11-15 2019-05-23 Ucb Biopharma Sprl Method for reducing the reconstitution time of spray-dried protein formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003055256A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
WO2019043008A1 (en) * 2017-08-31 2019-03-07 Xellia Pharmaceuticals Aps DAPTOMYCIN FORMULATIONS
WO2019096776A1 (en) * 2017-11-15 2019-05-23 Ucb Biopharma Sprl Method for reducing the reconstitution time of spray-dried protein formulations

Also Published As

Publication number Publication date
CN118873500A (zh) 2024-11-01
US20230068866A1 (en) 2023-03-02
ZA202208343B (en) 2024-11-27
CA3168727A1 (en) 2021-09-02
BR112022015571A2 (pt) 2022-09-27
MX2022010378A (es) 2022-09-21
AU2021227095B2 (en) 2024-02-22
AU2021227095A1 (en) 2022-08-25
JP2025142200A (ja) 2025-09-30
CN115038431B (zh) 2024-08-09
CN115038431A (zh) 2022-09-09
WO2021170807A1 (en) 2021-09-02
EP4110303A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
JP7229999B2 (ja) ダプトマイシン製剤
JP4077794B2 (ja) 抗新生物薬剤、特にテモゾロミドの薬学的処方物、その同一物の製造方法および使用方法
JP6041673B2 (ja) リポペプチド組成物および関連する方法
JP2023018090A (ja) 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用
EP2219605B1 (en) Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
JP2012167132A (ja) N−[o−(p−ピバロイルオキシベンゼンスルホニルアミノ)ベンゾイル]グリシン・モノナトリウム塩・4水和物の凍結乾燥製剤
AU2007321977A1 (en) Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure
CN115990138A (zh) 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法
JP2025142200A (ja) ダプトマイシン製剤
ES2342833T3 (es) Formulacion liofilizada estabilizada, para derivados de cefalosporina.
AU2006329849A1 (en) Lyophilized compositions of a triazolopyrimidine compound
WO2017085696A1 (en) Parenteral formulations of melphalan
AU2018328532A1 (en) Pharmaceutical composition of docetaxel conjugate and preparation method
JP4880845B2 (ja) Grf含有凍結乾燥薬剤組成物
AU2016364380B2 (en) Formulations for intravenous injection of danirixin
EP2968595A2 (en) Voriconazole formulations
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
JP2023510258A5 (enExample)
CN101669916A (zh) 一种硝苯地平冻干粉针的制备方法
WO2005123137A2 (en) Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride
HK1111344A (en) Stabilized freeze-dried formulation for cephalosporin derivatives
TW201302755A (zh) 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250430